abiraterone,olaparib
astrazeneca,merck
['prostate', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'propel']
key unknowns from #propel data #gu23 #prostatecancer 1. how many pts had mutations, but were not captured? and perhaps more importantly 2. for the hrrm patients, how many of them went on to receive parp inhibitor later on and how many did not? 
Clinical researcher focused on #ProstateCancer, early recurrence (#BCR)  & #immunotherapy. Views are my own & do not represent the National Cancer Institute